Related Experiment Video
Updated: Jul 18, 2026

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
Published on: May 21, 2017
Outcomes of Transcatheter Aortic Valve Replacement in Patients With Coexisiting Amyloidosis: Mortality, Stroke, and
Mohammed Elzeneini1, Shishir Gupta2, Yazan Assaf3
1Division of Cardiovascular Medicine, University of Florida, Gainesville, Florida, USA.
Insights
Cardiac amyloidosis patients undergoing transcatheter aortic valve replacement (TAVR) have a higher risk of stroke. However, amyloidosis did not significantly impact in-hospital mortality or 30-day readmission rates following TAVR.
Area of Science:
- Cardiology
- Interventional Cardiology
- Cardiac Imaging
Background:
- Cardiac amyloidosis frequently coexists with severe aortic stenosis.
- Limited data exists on the impact of cardiac amyloidosis on outcomes after transcatheter aortic valve replacement (TAVR).
Purpose of the Study:
- To investigate the effect of cardiac amyloidosis on in-hospital mortality, acute ischemic stroke, and 30-day readmission rates following TAVR.
Main Methods:
- Utilized the Nationwide Readmissions Database (2016-2019) to identify TAVR hospitalizations.
- Identified patients with and without a diagnosis of cardiac amyloidosis.
- Employed propensity score-weighted regression analysis to assess outcomes.
Main Results:
- Out of 245,020 TAVR hospitalizations, 273 involved patients with cardiac amyloidosis.
- No significant differences were observed in in-hospital mortality or 30-day readmission rates between groups.
- Patients with cardiac amyloidosis exhibited a significantly higher rate of acute ischemic stroke (6.2% vs 1.8%, P < 0.001).
- Logistic regression confirmed amyloidosis was associated with increased odds of acute ischemic stroke (OR: 3.08, P=0.005).
Conclusions:
- Cardiac amyloidosis may be associated with an elevated risk of thromboembolic events post-TAVR.
- Further research is warranted to explore this increased stroke risk in patients with cardiac amyloidosis undergoing TAVR.
Background:
Cardiac amyloidosis can coexist in patients with severe aortic stenosis. There are limited outcomes data on whether this impacts the risk of transcatheter aortic valve replacement (TAVR).
Objectives:
The authors aimed to investigate the effect of amyloidosis on outcomes of TAVR.
Methods:
We used the Nationwide Readmissions Database to identify hospitalizations for TAVR between 2016 and 2019. The presence of a diagnosis of amyloidosis was identified. Propensity score-weighted regression analysis was used to identify the association of amyloidosis with in-hospital mortality, acute ischemic stroke, and 30-day readmission rate after TAVR.
Results:
We identified 245,020 hospitalizations for TAVR, including 273 in patients with amyloidosis. The mean age was 79.4 ± 8.4 years. There was no difference in in-hospital mortality or 30-day readmission rate in patients with and without amyloidosis (1.8% vs 1.5%, P = 0.622; and 12.9% vs 12.5%, P = 0.858; respectively). However, there was a higher rate of acute ischemic stroke in patients with amyloidosis (6.2% vs 1.8%, P < 0.001). Propensity score-weighted logistic regression analysis showed the presence of amyloidosis was associated with greater odds of acute ischemic stroke (odds ratio: 3.08, 95% CI: 1.41-6.71, P = 0.005), but no difference in mortality (odds ratio: 0.79, 95% CI: 0.28-2.27, P = 0.666) or 30-day readmission rate after TAVR (HR: 0.72, 95% CI: 0.41-1.25, P = 0.241).
Conclusions:
This analysis suggests amyloidosis may be associated with a higher thromboembolic risk after TAVR that merits further investigation.
More Related Videos
14:14Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement
Published on: December 11, 2017
04:30Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat
Published on: February 4, 2021
Related Concept Videos
Aortic Regurgitation III: Medical Management
Endocarditis III: Medical Management
Acute Coronary Syndrome III: Diagnostic Studies
Atherosclerosis III: Management
Atherosclerosis IV: Nursing Management
Aneurysm III: Interprofessional Care